Cargando…
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979738/ https://www.ncbi.nlm.nih.gov/pubmed/33742086 http://dx.doi.org/10.1038/s41698-021-00162-7 |
_version_ | 1783667325722951680 |
---|---|
author | Smith, Corey McGrath, Margaret Neller, Michelle A. Matthews, Katherine K. Crooks, Pauline Le Texier, Laetitia Panizza, Benedict Porceddu, Sandro Khanna, Rajiv |
author_facet | Smith, Corey McGrath, Margaret Neller, Michelle A. Matthews, Katherine K. Crooks, Pauline Le Texier, Laetitia Panizza, Benedict Porceddu, Sandro Khanna, Rajiv |
author_sort | Smith, Corey |
collection | PubMed |
description | Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients. |
format | Online Article Text |
id | pubmed-7979738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79797382021-04-12 Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma Smith, Corey McGrath, Margaret Neller, Michelle A. Matthews, Katherine K. Crooks, Pauline Le Texier, Laetitia Panizza, Benedict Porceddu, Sandro Khanna, Rajiv NPJ Precis Oncol Case Report Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock for the successful implementation of ACT in clinical settings. Expression of checkpoint molecules by malignant cells can inhibit the effector function of adoptively transferred EBV-specific T cells. Here we present a novel case report of a patient with metastatic NPC who was successfully treated with a combination of EBV-specific ACT and programmed cell death-1 blockade therapy. Following combination immunotherapy, the patient showed complete resolution of metastatic disease with no evidence of disease relapse for 22 months. Follow-up immunological analysis revealed dramatic restructuring of the global T-cell repertoire that was coincident with the clinical response. This case report provides an important platform for translating these findings to a larger cohort of NPC patients. Nature Publishing Group UK 2021-03-19 /pmc/articles/PMC7979738/ /pubmed/33742086 http://dx.doi.org/10.1038/s41698-021-00162-7 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Case Report Smith, Corey McGrath, Margaret Neller, Michelle A. Matthews, Katherine K. Crooks, Pauline Le Texier, Laetitia Panizza, Benedict Porceddu, Sandro Khanna, Rajiv Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title | Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title_full | Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title_fullStr | Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title_full_unstemmed | Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title_short | Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma |
title_sort | complete response to pd-1 blockade following ebv-specific t-cell therapy in metastatic nasopharyngeal carcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979738/ https://www.ncbi.nlm.nih.gov/pubmed/33742086 http://dx.doi.org/10.1038/s41698-021-00162-7 |
work_keys_str_mv | AT smithcorey completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT mcgrathmargaret completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT nellermichellea completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT matthewskatherinek completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT crookspauline completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT letexierlaetitia completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT panizzabenedict completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT porceddusandro completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma AT khannarajiv completeresponsetopd1blockadefollowingebvspecifictcelltherapyinmetastaticnasopharyngealcarcinoma |